The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy

被引：104
作者：
Xu, Zihao [1 ,2 ,3 ]
Li, Peiyao [1 ,2 ,3 ]
Fan, Li [4 ]
Wu, Minghua [1 ,2 ,3 ]
机构：
[1] Cent S Univ, Hunan Prov Tumor Hosp, Xiangya Med Sch, Changsha, Hunan, Peoples R China
[2] Cent S Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha, Hunan, Peoples R China
[3] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Canc Res Inst, Minist Educ,Key Lab Carcinogenesis,Minist Hlth, Changsha, Hunan, Peoples R China
[4] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA
来源：
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
关键词：
circular RNAs; non-coding RNAs; tumor antigen; antitumor immunity; tumor immunotherapy; LONG NONCODING RNAS; CTLA-4; COUNTER-RECEPTOR; T-CELL DEVELOPMENT; CIRCULAR RNA; CHECKPOINT INHIBITORS; CANCER-IMMUNOTHERAPY; PD-1/PD-L1; BLOCKADE; MIRNA SPONGES; EXPRESSION; THERAPY;
D O I：
10.3389/fimmu.2018.00009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Non-coding RNAs (ncRNAs) can be divided into circular non-coding RNAs (circRNAs) and linear ncRNAs. ncRNAs exist in different cell types, including normal cells, tumor cells and immunocytes. Linear ncRNAs, such as long ncRNAs and microRNAs, have been found to play important roles in the regulation of tumor immunity and immunotherapy; however, the functions of circRNAs in tumor immunity and immunotherapy are less known. Here, we review the current status of ncRNAs in the regulation of tumor immunity and immunotherapy and emphatically discuss the potential roles of circRNAs as tumor antigens in the regulation of tumor immunity and immunotherapy.
引用
收藏
页数：11
相关论文
共 110 条
[1]   Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1 [J].
Abdelmohsen, Kotb ;
Panda, Amaresh C. ;
Munk, Rachel ;
Grammatikakis, Ioannis ;
Dudekula, Dawood B. ;
De, Supriyo ;
Kim, Jiyoung ;
Noh, Ji Heon ;
Kim, Kyoung Mi ;
Martindale, Jennifer L. ;
Gorospe, Myriam .
RNA BIOLOGY, 2017, 14 (03) :361-369
[2]   Cancer immunotherapies, their safety and toxicity [J].
Alatrash, Gheath ;
Jakher, Haroon ;
Stafford, Patricia D. ;
Mittendorf, Elizabeth A. .
EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) :631-645
[3]   Non-coding RNA networks in cancer [J].
Anastasiadou, Eleni ;
Jacob, Leni S. ;
Slack, Frank J. .
NATURE REVIEWS CANCER, 2018, 18 (01) :5-18
[4]   Mechanisms and Applications of Interleukins in Cancer Immunotherapy [J].
Anestakis, Doxakis ;
Petanidis, Savvas ;
Kalyvas, Spyridon ;
Nday, Christiane M. ;
Tsave, Olga ;
Kioseoglou, Efrosini ;
Salifoglou, Athanasios .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (01) :1691-1710
[5]  
[Anonymous], 2017, MERCK PROVIDES FURTH
[6]  
[Anonymous], 2017, MERCK PROVIDES UPDAT
[7]   Long non-coding RNAs and control of gene expression in the immune system [J].
Atianand, Maninjay K. ;
Fitzgerald, Katherine A. .
TRENDS IN MOLECULAR MEDICINE, 2014, 20 (11) :623-631
[8]   Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety [J].
Azoury, Said C. ;
Straughan, David M. ;
Shukla, Vivek .
CURRENT CANCER DRUG TARGETS, 2015, 15 (06) :452-462
[9]   Biochemical Signaling of PD-1 on T Cells and Its Functional Implications [J].
Boussiotis, Vassiliki A. ;
Chatterjee, Pranam ;
Li, Lequn .
CANCER JOURNAL, 2014, 20 (04) :265-271
[10]   Long noncoding RNAs in B-cell development and activation [J].
Brazao, Tiago F. ;
Johnson, Jethro S. ;
Muller, Jennifer ;
Heger, Andreas ;
Ponting, Chris P. ;
Tybulewicz, Victor L. J. .
BLOOD, 2016, 128 (07) :E10-E19
12345678910